Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a

Lifecore普通股股东将在交易完成时获得每股6.28美元的现金，相当于

49.5% Premium

49.5% 溢价

Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at Closing

Lifecore A轮优先股股东将在交割时以现金形式获得每股所需的“转换金额”

Both Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance Milestones

普通股股东和A轮优先股股东都将获得或有价值权（CVRs），在实现绩效里程碑的前提下，累计现金支付总额高达1.6亿美元

Stockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CVR at Full Performance Milestone Payments

在达到全部业绩里程碑付款条件时，股东每股普通股等价物最多可获得9.67美元的现金与或有价值权（CVR）组合对价

Transaction Expected to Support Lifecore’s Growth Objectives

交易预计将支持Lifecore的增长目标

CHASKA, Minn. and WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (Nasdaq: LFCR) today announced that it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, assuming full achievement of certain performance milestones..

明尼苏达州查斯卡和马萨诸塞州沃尔瑟姆，2026年9月28日（环球电讯社）——Lifecore Biomedical, Inc.（纳斯达克股票代码：LFCR）今日宣布，公司已与韦伯斯特股权合伙人（Webster Equity Partners）签订最终协议，将被其收购。假设某些绩效目标完全实现，该交易估值最高可达6.637亿美元。

“We are thrilled to announce this exciting transaction which we believe will support Lifecore’s next phase of growth,” said Paul Josephs, President and Chief Executive Officer of Lifecore. “Lifecore is approaching an exciting inflection point, with the potential for numerous programs to commercialize by the end of 2028. Following consideration of a range of alternatives, we believe that Webster Equity Partners shares our vision for maximizing Lifecore’s business and will provide us with additional resources and expertise to accelerate our growth.

“我们很高兴宣布这项令人振奋的交易，我们相信它将支持Lifecore的下一阶段增长，”Lifecore总裁兼首席执行官Paul Josephs表示。“Lifecore正迎来一个激动人心的转折点，到2028年底，有多个项目有望实现商业化。在考虑了各种替代方案后，我们认为Webster Equity Partners与我们有着共同的愿景，即最大化Lifecore的业务价值，并将为我们提供额外的资源和专业知识，以加速我们的增长。”

For our stockholders, this transaction delivers immediate and compelling value and is a testament to the contributions of the many stakeholders whose support, dedication, and hard work made this agreement possible.”.

对于我们的股东而言，此项交易带来了即时且显著的价值，也彰显了众多利益相关者的贡献，正是他们的支持、奉献与辛勤工作促成了本协议的达成。

Matthew Beer, Partner at Webster Equity Partners, said, “Our team is very excited to partner with Lifecore. Webster’s mission is to invest in and develop purpose-driven organizations that are dedicated to providing best-of-class service to customers. It is clear that Lifecore not only shares these goals but represents an exciting opportunity for growth in the mid-term and beyond.

Webster Equity Partners 合伙人马修·比尔表示：“我们的团队非常高兴能与 Lifecore 建立合作伙伴关系。Webster 的使命是投资并发展以使命为驱动的组织，这些组织致力于为客户提供一流的服务。显然，Lifecore 不仅与这些目标一致，而且代表着中期及未来令人兴奋的增长机遇。”

We are eager to pair our resources and experience with Lifecore’s CDMO expertise and capabilities as we pursue organizational excellence and sustainable profitability.”.

“我们渴望将我们的资源和经验与 Lifecore 的 CDMO 专业知识和能力相结合，以追求组织卓越和可持续的盈利能力。”

Under the terms of the agreement, an entity affiliated with Webster Equity Partners will acquire all outstanding Lifecore common stock for $6.28 per share in cash at closing plus one non-tradable contingent value right (CVR) per share. The holders of the Lifecore Series A Preferred Stock will be entitled to a payment in cash at closing equal to the “Conversion Amount” as defined in the Certificate of Designations relating to the Series A Preferred Stock as of the closing date, plus one non-tradable CVR per share of common stock into which the Series A Preferred Stock is convertible as of closing.

根据协议条款，与韦伯斯特股权合伙人（Webster Equity Partners）关联的一家实体将在交割时以每股6.28美元的现金收购Lifecore所有已发行的普通股，并为每股股份提供一项不可交易的条件价值权（CVR）。Lifecore A系列优先股的持有人有权在交割时获得一笔现金付款，金额等于截至交割日根据与A系列优先股相关的指定证书所定义的“转换金额”，再加上就每股在交割时可转换为的普通股对应的一项不可交易CVR。

As of June 30, 2026, the Conversion Amount was approximately $50.2 million, which represents an amount equal to $6.53 per share of Lifecore common stock into which the Series A Preferred Stock would have been converted as of such date. The Conversion Amount will be increased by dividends accrued through closing.

截至2026年6月30日，转换金额约为5,020万美元，相当于每股Lifecore普通股6.53美元，即在该日期A系列优先股本应转换成的普通股数量对应的金额。转换金额将增加截至交割日累计的股息。

The Series A Preferred Stock accrue dividends paid in kind at 7.5% per annum..

A系列优先股以实物支付形式按每年7.5%的利率累积股息。

The initial cash consideration of $6.28 per share of common stock represents a premium of approximately 49.5% to Lifecore’s closing price on September 25, 2026, the last full trading day prior to signing the merger agreement. Assuming full CVR performance milestone payments of $160 million, the aggregate potential merger consideration of $9.67 per share of common stock or common stock equivalent represents a premium of approximately 130.2% to Lifecore’s closing price on September 25, 2026, the last full trading day prior to signing the merger agreement..

每股普通股6.28美元的初始现金对价，较Lifecore在2026年9月25日（即签署合并协议前的最后一个完整交易日）的收盘价溢价约49.5%。假设全额支付1.6亿美元的或有价值权（CVR）业绩里程碑付款，则每股普通股或普通股等值证券的潜在合并对价总额将达到9.67美元，较Lifecore在2026年9月25日（即签署合并协议前的最后一个完整交易日）的收盘价溢价约130.2%。

Additional Transaction Details

附加交易详情

The transaction is expected to close at the end of the fourth quarter 2026, subject to the approval of Lifecore’s stockholders, the receipt of required regulatory approvals, and the satisfaction of certain other closing conditions. The Lifecore Transaction Committee and Lifecore Board of Directors have unanimously approved the merger agreement and recommend that Lifecore stockholders vote their shares to approve the transaction and adopt the merger agreement..

预计该交易将于2026年第四季度末完成，前提是获得Lifecore股东的批准、取得所需的监管批准，并满足其他某些交割条件。Lifecore交易委员会和Lifecore董事会已一致批准合并协议，并建议Lifecore股东投票赞成批准该交易并通过合并协议。

Webster Equity Partners has secured committed financing for the transaction. It has delivered to Lifecore a debt financing commitment letter from MidCap Financial Trust, MSD Partners, L.P. and Alcon Research, LLC, and an equity commitment letter from funds advised by Webster Equity Partners that, in the aggregate, are sufficient to fund the purchase price and pay related fees and expenses at closing..

韦伯斯特股权合伙人（Webster Equity Partners）已为该交易获得承诺融资。其已向 Lifecore 交付来自 MidCap Financial Trust、MSD Partners, L.P. 和 Alcon Research, LLC 的债务融资承诺函，以及由韦伯斯特股权合伙人顾问管理的基金出具的股权承诺函，上述承诺资金总额足以在交割时支付购买价款及相关费用和开支。

Upon completion of the transaction, Lifecore’s common stock will be delisted from the Nasdaq stock market. The Company expects to maintain its headquarters in Chaska, Minnesota, and to continue to operate under the Lifecore name and brand following closing.

交易完成后，Lifecore的普通股将从纳斯达克股票市场退市。公司预计将在交易结束后继续将其总部设在明尼苏达州查斯卡，并以Lifecore的名称和品牌继续运营。

The merger agreement includes a 30-day “go-shop” period, during which time Lifecore and its advisors may solicit, consider and negotiate alternative acquisition proposals from third parties. The Lifecore Board of Directors will have the right to terminate the merger agreement to enter into a transaction providing for a superior proposal, subject to the terms and conditions of the merger agreement.

合并协议包含一个30天的“招揽期”（go-shop period），在此期间，Lifecore及其顾问可以征求、审议并与第三方就替代性收购方案进行谈判。Lifecore董事会有权终止合并协议，以达成一项提供更优提案的交易，但须遵守合并协议的条款和条件。

There can be no assurance that this process will or will not result in a superior proposal. Lifecore does not intend to disclose updates on this process unless and until it determines that such disclosure is appropriate or required..

无法保证此过程是否会带来更优的提案。Lifecore 不打算披露此过程的最新进展，除非且直到其认为此类披露是适当或必要的。

As noted above, a non-tradable CVR will be issued to Lifecore stockholders and certain equity award holders at closing, and the rights of the CVR holders will be governed by the CVR agreement following closing. Under the CVR agreement, the CVR holders will receive cash payments contingent upon Lifecore’s achievement of revenue-based performance milestones for 2028 and 2029 and an EBITDA-based performance milestone for 2030.

如上所述，在交易交割时，将向Lifecore的股东及某些股权奖励持有人发行不可交易的或有价值权（CVR），且CVR持有人的权利将在交割后受CVR协议的约束。根据CVR协议，CVR持有人将获得基于Lifecore在2028年和2029年实现的收入相关绩效里程碑以及在2030年实现的息税折旧摊销前利润（EBITDA）相关绩效里程碑而支付的现金款项。

The payout on the CVRs is $30 million for achievement of the 2028 performance milestone, $45 million for achievement of the 2029 performance milestone, and $85 million for achievement of the 2030 performance milestone, subject to catch-up in 2029 on the 2028 milestone payment and other adjustments. In the aggregate, stockholders may receive up to $9.67 per share of common stock or common stock equivalent based upon the cash consideration at closing and assuming full performance milestone payments of $160 million in the aggregate..

就或有价值权（CVR）而言，实现2028年业绩里程碑的支付金额为3,000万美元，实现2029年业绩里程碑的支付金额为4,500万美元，实现2030年业绩里程碑的支付金额为8,500万美元，但须受限于2029年对2028年里程碑付款的补足机制及其他调整。总体而言，基于交割时的现金对价并假设总计1.6亿美元的业绩里程碑付款全额支付，股东每股普通股或同等普通股可获得高达9.67美元的对价。

The following table provides an illustration of the CVR performance milestones, milestone payments, and milestone payment amounts per share of common stock and Series A Preferred Stock, assuming full payment of each CVR milestone, which cannot be assured (in millions except per share amounts):

下表列示了或有价值权利（CVR）的业绩里程碑、里程碑付款以及每股普通股和A系列优先股的里程碑付款金额，假设每个CVR里程碑均获全额支付（该等支付无法保证）（除每股金额外，以百万计）：

Cash at

现金位于

Closing

闭幕

Milestone Payment and Year

里程碑付款及年份

Total

总计

$30

30美元

$45

45美元

$85

85美元

CVR Performance Milestones

CVR 性能里程碑

2028

2028

2029

2029

2030

2030

(a) Revenue from all customers excluding Alcon AND

(a) 除爱尔康以外的所有客户收入，且

$120

120美元

$175

175美元

n/a

不适用

(b) either

(b) 要么

(i) Revenue from Alcon OR

(i) 来自爱尔康或的收入

$54

54美元

$53

53美元

n/a

不适用

(ii) Revenue from all customers

（ii）来自所有客户的收入

$174

174美元

$228

228美元

n/a

不适用

Consolidated EBITDA

合并息税折旧摊销前利润

n/a

不适用

n/a

不适用

$120

120美元

Common Stock Per Share

每股普通股

(3)

（3）

$6.28

6.28美元

$0.67

0.67美元

$0.94

0.94美元

$1.78

1.78美元

$9.67

9.67美元

Series A Preferred Stock Per Common Equivalent

A轮优先股每股普通股等价物

(4)

(4)

$6.53

6.53美元

$0.42

0.42美元

$0.94

0.94美元

$1.78

1.78美元

$9.67

9.67美元

(1) Subject to scaling factor and catch-up payment as further described in the CVR agreement.

(1) 须受缩放因子及补差支付的约束，详见CVR协议中的进一步描述。

(2) Subject to scaling factor as further described in the CVR agreement.

(2) 受限于CVR协议中进一步描述的缩放因子。

(3) Cash closing merger consideration is a fixed amount of $6.28 per share of common stock. CVR amounts per share of common stock include CVRs issuable at closing to holders of certain Company equity awards in accordance with the terms of the merger agreement, based upon shares of common stock and Company equity awards outstanding as of the date of the merger agreement.

(3) 现金交割合并对价为每股普通股6.28美元的固定金额。每股普通股对应的或有价值权（CVR）金额包括根据合并协议条款，在交割时向某些公司股权奖励持有人发行的CVR，该金额基于合并协议签署之日已发行的普通股及公司股权奖励数量计算。

.

。

(4) For Series A Preferred Stock, $6.53 represents amount per share of Lifecore common stock into which the Series A Preferred Stock would be converted. In the case of the CVR amounts for the Series A Preferred Stock, assumes the number of shares of Series A Preferred Stock outstanding as of December 31, 2026 and treatment in accordance with the Certificate of Designations relating to the Series A Preferred Stock..

(4) 就A系列优先股而言，6.53美元代表每股可转换为的Lifecore普通股的金额。在涉及A系列优先股的或有价值权（CVR）金额时，假设截至2026年12月31日已发行的A系列优先股数量，并按照与A系列优先股相关的指定证书进行处理。

The table above is illustrative only and qualified in its entirety by the terms and conditions of the Merger Agreement and the CVR agreement, and excludes any adjustment for litigation as specified in the CVR agreement. CVR amounts per share will change based upon the number of outstanding shares of common stock, shares of Series A Preferred Stock and shares underlying certain Company equity awards, as well as the Conversion Amount, as of the closing date of the proposed Merger..

上述表格仅供参考，并完全受《合并协议》和《或有价值权（CVR）协议》的条款和条件的约束，且不包括《或有价值权（CVR）协议》中规定的任何诉讼调整。每股CVR金额将根据拟议合并截止日期的已发行普通股数量、A系列优先股数量以及某些公司股权奖励所对应的股份数量，以及转换金额的变化而变化。

Advisors

顾问

Bourne Capital Partners, L.L.C. is serving as exclusive M&A advisor to Lifecore. Craig-Hallum Capital Group LLC also served as a financial advisor to the Transaction Committee and the Board of Directors of Lifecore. Ballard Spahr LLP is serving as legal counsel to Lifecore and its Board of Directors.

伯恩资本合伙有限责任公司（Bourne Capital Partners, L.L.C.）担任 Lifecore 的独家并购顾问。克雷格-哈勒姆资本集团有限责任公司（Craig-Hallum Capital Group LLC）亦担任 Lifecore 交易委员会及董事会的财务顾问。巴拉德·斯帕尔律师事务所（Ballard Spahr LLP）担任 Lifecore 及其董事会的法律顾问。

Zukerman Gore Brandeis & Crossman, LLP is serving as legal counsel to the Lifecore Transaction Committee. Morgan Stanley & Co. LLC is serving as the exclusive financial advisor and Goodwin Procter LLP is serving as legal counsel to Webster Equity Partners..

Zukerman Gore Brandeis & Crossman, LLP 担任 Lifecore 交易委员会的法律顾问。Morgan Stanley & Co. LLC 担任 Webster Equity Partners 的独家财务顾问，Goodwin Procter LLP 担任其法律顾问。

About Lifecore Biomedical

关于 Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations.

Lifecore Biomedical, Inc.（纳斯达克股票代码：LFCR）是一家完全整合的合同研发与生产组织（CDMO），在预充式注射器、西林瓶和卡式瓶等无菌注射药品的开发、灌装及封口方面提供高度差异化的能力，涵盖复杂制剂。

As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

作为优质注射级透明质酸的领先制造商，Lifecore 凭借四十余年的专业经验，携手全球及新兴的生物制药和生物技术公司，跨越多个治疗领域，助力其创新成果推向市场。欲了解更多公司信息，请访问 Lifecore 官网 www.lifecore.com。

The contents of Lifecore’s website are not incorporated by reference into this press release..

Lifecore网站的内容并未通过引用方式纳入本新闻稿。

About Webster Equity Partners

关于韦伯斯特股权合伙人

Webster Equity Partners is a leading middle market private equity firm focused exclusively on investing in healthcare services companies. The firm partners with exceptional management teams to drive growth and value creation through strategic guidance, operational support, governance, industry relationships, and disciplined long-term capital deployment.

韦伯斯特股权合伙公司是一家领先的中端市场私募股权投资机构，专注于投资医疗服务企业。该公司与卓越的管理团队合作，通过战略指导、运营支持、公司治理、行业关系以及审慎的长期资本配置，推动增长并创造价值。

Webster is based in Waltham, Massachusetts. For more information, please visit www.websterequitypartners.com. The contents of Webster’s website are not incorporated by reference into this press release..

韦伯斯特公司总部位于马萨诸塞州沃尔瑟姆。欲了解更多信息，请访问 www.websterequitypartners.com。韦伯斯特网站的内容并未通过引用方式纳入本新闻稿。

Caution Regarding Forward-Looking Statements

关于前瞻性陈述的警示

This communication relates to the proposed transaction pursuant to which Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) will be acquired by Lifecore Inc., a Delaware corporation (“Parent”). Pursuant to an Agreement and Plan of Merger dated September 27, 2026 (the “Merger Agreement”), Hazel Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Parent, will be merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

本函件涉及拟议交易，根据该交易，Lifecore Biomedical, Inc.（“Lifecore”或“公司”）将由特拉华州公司 Lifecore Inc.（“母公司”）收购。根据日期为2026年9月27日的《合并协议与计划》（“合并协议”），母公司的全资子公司、特拉华州公司 Hazel Merger Sub, Inc.（“合并子公司”）将与公司合并并并入公司（“合并”），公司在合并后存续，并成为母公司的全资子公司。

Parent and Merger Sub are affiliates of Webster Equity Partners..

母公司及合并子公司均为韦伯斯特股权合伙公司的关联方。

This communication contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can often, but not always, be identified by the use of words like “believe”, “continue”, “pattern”, “plan”, “forecast,” “estimate”, “project”, “intend”, “anticipate”, “expect” and similar expressions or future or conditional verbs such as “will”, “would”, “should”, “could”, “might”, “can”, “may”, or similar expressions.

本通讯包含根据1995年《私人证券诉讼改革法》的安全港条款作出的前瞻性陈述。此类前瞻性陈述通常（但并非总是）可以通过使用“相信”、“继续”、“模式”、“计划”、“预测”、“估计”、“规划”、“打算”、“预期”、“期望”等词语或类似表述，或者使用“将”、“会”、“应该”、“能够”、“可能”、“可以”、“也许”等将来时或条件式动词或类似表述来识别。

These forward-looking statements include, but are not limited to, statements relating to the expected timing of the Merger, closing conditions relating to the Merger, and expectations, goals, projections and benefits relating to the Merger, as well as other statements regarding Lifecore’s goals, intentions and expectations, business plan and growth strategies, and the anticipated future performance of Lifecore, whether with respect to the Merger or otherwise..

这些前瞻性陈述包括但不限于，有关合并预期时间的陈述、与合并相关的交割条件、以及与合并相关的预期、目标、预测和益处，还有关于 Lifecore 的目标、意图和期望、业务计划和增长战略，以及 Lifecore 预期未来表现的其他陈述，无论是否与合并相关。

Forward-looking statements are not historical facts but instead express only Lifecore’s management’s beliefs regarding future results or events, many of which, by their nature, are inherently uncertain and outside of management’s control. Actual results and outcomes may differ, possibly materially, from the anticipated results or outcomes indicated in these forward-looking statements because of risks and uncertainties, including, but not limited to: (1) the proposed transaction may not be completed in a timely manner or at all, which may adversely affect Lifecore’s business and the price of its common stock; (2) the failure to satisfy any of the conditions to the consummation of the transaction, including the receipt of certain regulatory approvals; (3) the failure to obtain stockholder approval of the transaction; (4) the occurrence of any fact, event, change, development or circumstance that could give rise to the termination of the transaction agreement, including in circumstances requiring Lifecore to pay a termination fee; (5) the risk that Lifecore’s rights under the Merger Agreement to pursue or consider a “Superior Proposal” will not result in a “Superior Proposal”; (6) the value to stockholders from the contingent value rights (CVRs) that Lifecore will distribute to its stockholders is uncertain and the holders of the CVRs may receive less-than-anticipated payments (or no payments) with respect to the CVRs after the closing of the proposed transaction; (7) the proposed transaction and its announcement could have an adverse effect on the ability of Lifecore to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders and other business relationships and on its operating results and business generally; .

前瞻性陈述并非历史事实，而仅表达 Lifecore 管理层对未来业绩或事件的信念，其中许多信念因其性质而具有固有的不确定性，且不在管理层的控制范围内。由于各种风险和不确定性，实际结果和 outcome 可能与这些前瞻性陈述中指明的预期结果或 outcome 存在差异，甚至可能存在重大差异，这些风险和不确定性包括但不限于：(1) 拟议交易可能无法及时完成或根本无法完成，这可能对 Lifecore 的业务及其普通股价格产生不利影响；(2) 未能满足完成交易的任何条件，包括获得某些监管批准；(3) 未能获得股东对交易的批准；(4) 发生任何可能导致终止交易协议的事实、事件、变化、发展或情况，包括在要求 Lifecore 支付终止费的情况下；(5) Lifecore 根据合并协议追求或考虑“更优提案”的权利可能不会带来“更优提案”的风险；(6) Lifecore 将向其股东分派的或有价值权（CVRs）对股东的价值存在不确定性，且在拟议交易完成后，CVR 持有人就 CVRs 收到的付款可能低于预期（或无付款）；(7) 拟议交易及其公告可能对 Lifecore 保留和聘请关键人员以及维持与客户、供应商、合作伙伴、员工、股东和其他商业关系的能力产生不利影响，并可能对其经营业绩和整体业务产生不利影响。

Additional Information and Where to Find It

附加信息及查询途径

In connection with the proposed acquisition of Lifecore by an affiliate of Webster Equity Partners, Lifecore will file with the SEC a definitive proxy statement relating to a Lifecore special meeting of stockholders to approve the Merger Agreement and the Merger.

就韦伯斯特股权合伙人（Webster Equity Partners）的关联公司拟收购Lifecore一事，Lifecore将向美国证券交易委员会（SEC）提交一份最终委托书声明，该声明涉及召开Lifecore股东特别会议，以批准合并协议及合并交易。

Lifecore urges you to read the proxy statement and other relevant documents filed or to be filed with the SEC carefully as they become available, as well as any amendments or supplements to these documents, because they will contain important information.

Lifecore 敦促您仔细阅读向美国证券交易委员会（SEC）提交或即将提交的委托声明书及其他相关文件，以及这些文件的任何修订或补充材料，因为它们将包含重要信息。

You will be able to obtain a free copy of the proxy statement and other related documents (when available) filed by Lifecore with the SEC at the website maintained by the SEC at www.sec.gov. You also will be able to obtain a free copy of the proxy statement and other documents (when available) filed by Lifecore with the SEC by accessing the investor relations section of Lifecore’s website at https://ir.lifecore.com or by calling (952).

您可以在美国证券交易委员会（SEC）维护的网站 www.sec.gov 上免费获取 Lifecore 向 SEC 提交的代理声明及其他相关文件（如有）。您还可以通过访问 Lifecore 网站的投资者关系栏目（https://ir.lifecore.com）或致电 (952)，免费获取 Lifecore 向 SEC 提交的代理声明及其他文件（如有）。

368-4300. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement or any other document that Lifecore files with or furnishes to the SEC.

368-4300。上述网站的内容不被视为通过引用方式纳入Lifecore向美国证券交易委员会（SEC）提交或提供的代理声明或其他任何文件中。

Participants in the Solicitation

招标参与者

This communication does not constitute a solicitation of proxy, an offer to sell or a solicitation of an offer to sell any securities. Lifecore and its directors and executive officers may be deemed to be participants in the solicitation of proxies from Lifecore stockholders in connection with the proposed transaction..

本沟通不构成征求委托书、出售要约或征求任何证券的出售要约。Lifecore 及其董事和高级管理人员可能被视为在与拟议交易相关的向 Lifecore 股东征求委托书过程中的参与者。

Information regarding the directors and executive officers of Lifecore, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth (1) in Lifecore’s definitive proxy statement for its 2026 Annual Meeting of Stockholders, including under the headings “Proposal No.

有关Lifecore董事及高级管理人员的信息，包括对其通过证券持有或其他方式直接或间接权益的描述，载于（1）Lifecore就其2026年年度股东大会发布的最终委托书声明中，包括在“提案编号”标题下。

1: Election of Directors,” “Corporate Governance and Board Matters – Executive Officers of the Company,” “Compensation Discussion and Analysis,” “Executive Compensation and Related Information,” “Stock Ownership of Certain Beneficial Owners and Management” and “Certain Relationships and Related Party Transactions,” which was filed with the SEC on April 24, 2026, and (2) to the extent holdings of Lifecore’s securities by its directors or executive officers have changed since the amounts set forth in Lifecore’s definitive proxy statement for its 2026 Annual Meeting of Stockholders, such changes have been or will be reflected on Initial Statement of Beneficial Ownership of Securities on Form 3, Statement of Changes in Beneficial Ownership on Form 4, or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC.

1：董事选举”、“公司治理及董事会事项——公司高级管理人员”、“薪酬讨论与分析”、“高管薪酬及相关信息”、“某些受益所有人及管理层的股票所有权”和“某些关系及关联方交易”，该文件已于2026年4月24日向美国证券交易委员会（SEC）提交；以及（2）若自Lifecore公司2026年年度股东大会最终委托书中所列金额以来，其董事或高级管理人员持有的Lifecore证券发生变动，则该等变动已在或将反映在向SEC提交的3号表格（初始受益所有权声明）、4号表格（受益所有权变动声明）或5号表格（受益所有权年度变动声明）中。

These documents can be obtained free of charge in the manner described above under “Additional Information and Where to Find It.”.

上述文件可按“附加信息及获取途径”中所述方式免费获取。

Contacts:

联系人：

For Lifecore:

致Lifecore：

Ryan D. Lake (CFO)

瑞安·D·莱克（首席财务官）

Lifecore Biomedical

力科生物医疗

952-368-6244

952-368-6244

ryan.lake@lifecore.com

ryan.lake@lifecore.com

Stephanie Diaz (Investors)

斯蒂芬妮·迪亚兹（投资者）

Vida Strategic Partners

维达战略合作伙伴

415-675-7401

415-675-7401

sdiaz@vidasp.com

sdiaz@vidasp.com

Jennifer Arcure (Media)

詹妮弗·阿库雷（媒体）

Vida Strategic Partners

维达战略伙伴

917-603-0681

917-603-0681

jarcure@vidasp.com

jarcure@vidasp.com

For Webster Equity Partners:

代表韦伯斯特股权合伙公司：

IR@websterequitypartners.com

IR@websterequitypartners.com